Objective: Literature reviews suggest limited evidence of efficacy of antidepressant medication in patients with advanced cancer. This study was carried out to observe the longitudinal effect of antidepressant medication in a cohort of advanced cancer patients. Method: Patients were recruited from hospice day care settings and followed up longitudinally by series of measures for depression for 6 months or until death. Results: Six hundred and twenty nine patients recruited. One hundred and fifty six patients in total (25%) were receiving antidepressant medication for a median of 9.5 weeks (range 0-36 weeks) and a mean of 12.2 weeks. There was no significant difference in scores on depression measures over time for patients receiving antidepressant medication. Conclusions: Antidepressant medication for advanced cancer patients appeared to have little impact on depression scores. We postulate the holistic approaches within hospice day care may in themselves be interventions for depression thereby masking effect of pharmacological treatment. Further research should explore multi-intervention models for management of depression in advanced cancer.
Introduction
Despite many developments in assessment and treatment of symptoms in advanced cancer, depression continues to prove a challenge both in terms of assessment and treatment. [1] [2] [3] [4] It is routine within palliative care services to incorporate tools for screening of physical symptoms and there are also many validated tools for assessment of depression in patients with advanced cancer, [5] [6] [7] [8] although it is not known how embedded such tools are within clinical practice. The management of depression in advanced cancer should be holistic and collaborative in its approach. 9 Systematic reviews of interventions for cancer patients (including advanced cancer) reported limited evidence for the effectiveness of both pharmacological and psychosocial interventions and no evidence for the superiority of one treatment modality over another 10, 11 and report a need for randomised trials to determine effectiveness of antidepressants in patients with advanced metastatic cancer. A recent randomised trial of cognitive behavioural therapy in advanced cancer patients 12 found a significant decrease in anxiety but not depression. We report the findings of observed effect of antidepressant medication on depression scores as measured by Edinburgh depression scale (EDS) and Patient Health Questionnaire 9 (PHQ9) in a large longitudinal study of 629 patients recruited from hospice day care settings.
Patients and methods

Design and study
This study was carried out in hospice day units in North West of England. Recruitment into the study started on 1 November 2007 and all follow-ups were completed by 1 August 2009.
Patients
Consecutive patients were recruited from hospice day care units in the North West Region. The inclusion criteria were patients with locally advanced or metastatic disease over the age of 18 years and estimated by hospice day care staff to have prognosis of 6 months in order to be able to complete the followup for the study. There was no upper age limit for the study. Exclusion criteria were not being able to speak or read English; a non-cancer diagnosis and cognitive impairment.
Procedure
Eligible consecutive patients were informed about the study by the senior nurse at their hospice day care unit and a brief letter introducing the study was given. Patients interested in the study were invited to complete a reply slip to ask a researcher to contact them. All patients contacted by the researcher, received detailed information and were asked to give written consent prior to participating in the study. The majority of interviews at baseline were conducted in the hospice or within the patient's own home by a researcher and the baseline interview occurred as soon as was practical following consent being obtained. Patients were asked how they wished to complete subsequent follow-up questionnaires-usually patients completed follow-up questionnaires by post, with a small number opting for telephone or face-to-face contact. Any patient found to be a case of depression on either of the depression measures at any time point were referred onto the day care senior nurse and managed according to each unit's clinical practice. Full ethical approval for the study was obtained from the Research Ethics committee 07/Q1505/24.
Questionnaires
Patients were invited to complete two assessment tools for depression namely PHQ 9 and EDS. The EDS 13 is a 10-item scale and has been previously validated in palliative care patients and found to have acceptable validity 5 and is widely used in screening for depression in palliative care. The PHQ9 is a self-report measure and consists of nine items selected to assess the presence of the DSM-IV criteria for Major Depressive Episode using a 4-point response scale and has validated cut-offs for mild, moderate and severe depression. 6 All participants also completed the Demoralisation Scale; 14 Royal Free Beliefs and Values Scale, 15 and a patient reported outcomes physical symptom questionnaire constructed for the study-the data from which will be reported elsewhere. All patients were assessed for cognitive function using the Abbreviated Mental Test Score (AMTS) 16 -a 10-point dichotomous scale with a score of 6 or less indicative of cognitive impairment-none of the patients recruited scored 6 or less and this is to be expected-these patients would have been screened out by clinic staff and also recruitment process of asking patients to complete form for initial contact with researcher may have additionally screened out further patients with cognitive impairment.
At baseline, independent variables were collected including age, sex, marital status, past history of depression, site of primary cancer and metastases, date of diagnosis, mode of communication of cancer diagnosis, current medication including antidepressant medication. At 8, 16 and 24 weeks patients were invited to complete the EDS, PHQ9, patient reported outcomes for symptoms scale and the demoralisation scale and to record information regarding medication. We relied on patients own reports of whether they were taking antidepressant medication and did not corroborate this with clinical records. Performance status was assessed using ECOG performance status 17 which is scored from 0-4-a score of 0 indicating no dependence and 4 maximum dependence.
Statistical analysis
Date was managed via the MACRO database and this study was supported by the Cancer Trials Unit. Statistical significance was set at P < 0.05 and analyses were conducted in the statistical package R version 2.9.2 for windows. Descriptive statistics were calculated along with confidence intervals. The Fisher's exact test, t-test or Mann-Whitney U test was used to examine univariate associations between independent variables and depression where appropriate. A linear mixed effect model for sub-groups including time and use of antidepressant was carried out and the model included a random intercept to allow variations between patients at baseline.
Recruitment and attrition
A total of 921 consecutive patients who met eligibility criteria were given information leaflets by day care staff; 694 patients requested the researcher to contact them and 629 patients participated in the study ( Table 1 ). The main reasons for non-participation were patients not feeling well enough to participate in a 6-month longitudinal study. Six hundred and twenty nine patients completed baseline measures; 494 patients (78.5%) completed 8-week follow-up; 405 (64.3%) completed 16-week follow-up and 349 (55.5%) completed 24-week follow-up. Three hundred and forty nine patients (55.5%) completed assessments at each time point. One hundred and thirty nine patients (22%) died during 6-month follow-up and 235 patients (37.4%) died during the study period. The diagnoses of patients included 32% breast cancer, 17% gastrointestinal and 12% lung cancer and most cancer diagnoses were included in the sample recruited. At recruitment the ECOG performance status of patients was recorded as 42% ECOG 1; 28% ECOG 2; 21% ECOG 3; 4% ECOG of 4. The age range of patients recruited was 21-94 years-mean age 66 years; 67% of patients recruited were female and 323 patients (51%) married. The majority (97%) regarded their ethnicity as white British and the median time since initial cancer diagnosis was 3 years. The overall median survival of patients recruited into the study was 37.1 weeks (95% CI-36.0, 39.9 weeks) (range 0-116 weeks).
Frequency of depression
Two hundred and fourteen patients (34%) reported previous episodes of depression prior to their cancer diagnosis. The PHQ9 has validated cut-offs for whether depression is thought to be mild (5-9), moderate (10) (11) (12) (13) (14) or severe (15+). At baseline/recruitment assessment, 32% of patients scored for moderate or severe symptoms of depression with 11% of patients scoring 15 or above suggesting severe symptoms. The EDS has a validated cut-off of 13 for cases of depression and 17% scored 13 or greater on the EDS at baseline/recruitment assessment.
Antidepressant medication
At each time point patients were asked to state whether they were taking antidepressant medication for depression, to record the drug and the dose and when commenced. One hundred and fifty six patients (25%) were taking antidepressant medication for depression at some point during the 6-month study period. We considered a cut-off on PHQ9 of 10 or above as indicative of moderate or severe depression, approximately a third of all patients who scored 10 or above on PHQ9 at each time point were receiving antidepressant medication (Table 2) None of the patients in the study had been prescribed Tricyclic Antidepressants for their depression with majority of patients (77%) being prescribed Selective Serotonin Reuptake Inhibitors and remainder being prescribed Noradrenergic and Specific Serotonergic antidepressant medication. All patients were prescribed medication within the recommended therapeutic dose ranges. Patients were taking antidepressant medication for a median of 9.5 weeks (range 0-36 weeks) and a mean of 12.2 weeks. Patients stating they were taking antidepressant medication had significantly higher scores on both EDS (score 3.18 points higher; 95% CI-4.99 to À1.38; =0.002) and PHQ9 (score 2.71 points higher; 95% CI-4.47 to À0.85; P = 0.0043) than those not taking antidepressants across all time points (Figure 1 ).
Are antidepressants effective in patients with highest quartile of depression scores?
We examined our data as it would be expected that if antidepressant medication demonstrated an effect on depression scores, this effect would be greatest for patients with highest depression scores. The PHQ9 has pre-determined cut-off thresholds for severity of depression. A linear mixed effect model for these sub-groups including time and use of antidepressant was fitted which included a random intercept to allow variations between patients at baseline. On average, there was no significant difference in PHQ9 over time between those who were on antidepressant medication and for those who were not on antidepressant medication (coefficient 0.85; 95% CI-0.75, 2.46; P-val 0.2965 and coefficient 0.03; 95% CI-1.48, 1.54; P-val 0.9682, respectively, for the highest and the lowest quartile). The change in PHQ9 over time between patients who were on and not on antidepressant was also not significant (coefficient 0.01; 95% CI-0.01, 0.02; P-val 0.2844 and coefficient 0.01; 95% CI-0.00, 0.02; P-val 0.0613, respectively, for the highest and the lowest quartile) (Figure 2 ).
Discussion
The management of depression in advanced cancer frequently employs a combination of antidepressant medication along with psychosocial interventions which may include supportive listening, diversion activities or cognitive behavioural therapy. The results of this observational study suggest that antidepressants, did not appear to influence depression scores in a large longitudinal cohort of patients with advanced cancer attending hospice day care units. Depression was a significant symptom for many patients in our study and using the pre-determined cut-off thresholds on PHQ 9, at baseline 32% of patients scored for moderate or severe symptoms of depression with 11% scoring 15 or above suggesting severe symptoms. One hundred and fifty six of the 629 patients in the study (25%) were taking antidepressant medication for depression at some point during the 6-month study follow-up period for a median of 9.5 weeks (range 0-36 weeks) and a mean of 12.2 weeks. A rate of decline was observed for depression using both depression tools over follow-up-supporting a recent study with a 4-week follow-up which suggested that depression remits over time in patients with advanced cancer. 17 Two validated tool; the EDS and PHQ9, were used in this study and the PHQ9 has previously reported data in longitudinal studies. 18, 19 The findings that there was no difference in PHQ9 scores for patients whose scores were in highest quartile and who were receiving antidepressants is at variance with recent research in this area 20 and the findings of a recent meta-analysis that antidepressants were superior to placebo and effect increased with continued use. 21 Our observational study is much larger than the majority of studies of antidepressant medication in patients with advanced cancer. 22 All patients in this study were recruited from hospice day care units. We did not collect data on whether patients were receiving specific psychological interventions for depression, however the reported lack of specialist psychological services within palliative care and hospices 23 suggests it would be very unlikely for patients in this study to be accessing these services. In hospice day care the emphasis is holistic care, social interaction and support. A qualitative study 24 reported patients' subjective well-being and improved mood on attending day care and the beneficial effects attendance had on well-being. A systematic review of 12 studies concluded that palliative care patients valued a person-centred approach that reduces isolation, increases social support, encourages communication and provides activities. 25 We suggest that the psychosocial support afforded by attending hospice day care may in part explain the possible lack of benefit of antidepressant medication in these observational findings. We cannot conclude that antidepressants are not effective in hospice day care patients as we are not reporting the findings of a randomised controlled trial, but we believe that further research should explore in greater detail the psychosocial benefits of attending hospice day care and that possibly day care could be utilised by referring patients with the most complex psychosocial needs including depression. Research in non-cancer community settings has shown that interventions such as social networks 26 can improve psychological wellbeing. Palliative care patients who are depressed also require a co-ordinated approach to their care which may include pharmacological medication and psychological interventions but we may be underestimating and not researching the social and well-being interventions which may benefit palliative care patients with depression.
Limitations
We report observational findings in this large longitudinal study of palliative care patients attending hospice day care. We did not carry out structured clinical interviews to diagnose depression however, utilised well-validated tools and we acknowledge that this study does not have the rigour of a randomised controlled trial. We relied on patient reports as to whether they were receiving antidepressant medication and clearly although patients reported they were prescribed antidepressant medication it was not possible to directly monitor compliance. However, we believe this large longitudinal study does contribute to the literature in this area.
Clinical implications
The observational findings from this study suggest that antidepressant medication had little impact in reducing depression scores for patients attending a hospice day care service. We suggest that the holistic approach within hospice day care alongside the integral social support and diversional activities may in themselves be interventions for depression thereby masking/minimising the effect of pharmacological interventions and that further studies are necessary to explore what may be the most appropriate multi-intervention model for management of depression in palliative care patients.
